Valganciclovir

An ester of ganciclovir, it inhibits viral DNA synthesis. It is given for the initial treatment and maintenance treatment of CMV retinitis in AIDS patients. It is also effective in prevention of CMV disease in transplant recipients.

Brands
VALCYTE
Adult Dose
Neonatal
Paedriatic
Characteristics
. It is of Synthetic origin. .
Contraindications
Valganciclovir
Effects
The symptomatic adverse reactions produced by Valganciclovir are more or less tolerable and if they become severe, they can be treated symptomatically, these include Flatulence, Dizziness, Headache, Ataxia, Anorexia, Diarrhea, Fever, Myalgia, Anxiety, Constipation, Abdominal pain, Sweating, Dry mouth, Rashes, Pruritus, Gastritis, Mouth ulcers, Dysuria, Photosensitivity, Dyspepsia, Sleep disturbance, Hypotension, Coma, Psychosis, Tremor, Arthralgia, Nausea and vomiting, Dry skin, Acne, Dysphagia, Chest pain, Esophagitis, GI hemorrhage, Fecal incontinence, Paresthesias, Hypertension, Migraine, Amnesia, Hearing disturbances, Myasthenia, Injection-site reactions, Breast pain, Eye or ear pain, Hyperkinesia, Abnormal dreams, Seizures.
Indications
Valganciclovir is primarily indicated in conditions like Acid reflux disease (long-term management), Cytomegalovirus retinitis in aids patients.
Interactions
Valganciclovir is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAbacavir These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Risks
If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
Valganciclovir should be used with exterme caution and there should be a close monitoring of blood counts (dose adjstment or interruption may be required); history of cytopenia; low platelet count; potential carcinogen and teratogen; renal impairment; ensure adequate hydration during I/V adminstration; vesicant---infuse into vein with adequate flow preferably using a plastic cannula; limited experience in children (possible risk of long-term carcinogenic or reproductive toxicity-----not for neonatal or congenital cytomegalovirus disease)
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.